Can sodium-glucose cotransporter 2 (SGLT2) inhibition preserve renal structure and function in de novo kidney transplant recipients? Protocol for a randomised, double-blind, placebo-controlled trial assessing the efficacy of dapagliflozin on kidney structure, function and safety in kidney transplant recipients in Norway—the DEAK study

Ingrid Charlotte Kongerud, Karsten Midtvedt, Marit D Solbu, Marius A Øvrehus, Øystein Eikrem, Ivar A Eide, Kristian Heldal, Kåre Birkeland, Anders Åsberg, Trond G Jenssen

Open source

DOI: 10.1136/bmjopen-2026-117263
Published: 2026-06
Container: BMJ Open
Publisher: BMJ
Open access: unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

supportingDOI registered: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
supportingDOI resolves: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
supportingMetadata completeness: All 6 scored descriptive metadata groups are present. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1136/bmjopen-2026-117263,
  title = {Can sodium-glucose cotransporter 2 (SGLT2) inhibition preserve renal structure and function in de novo kidney transplant recipients? Protocol for a randomised, double-blind, placebo-controlled trial assessing the efficacy of dapagliflozin on kidney structure, function and safety in kidney transplant recipients in Norway—the DEAK study},
  author = {Ingrid Charlotte Kongerud and Karsten Midtvedt and Marit D Solbu and Marius A Øvrehus and Øystein Eikrem and Ivar A Eide and Kristian Heldal and Kåre Birkeland and Anders Åsberg and Trond G Jenssen},
  year = {2026},
  journal = {BMJ Open},
  doi = {10.1136/bmjopen-2026-117263},
  url = {https://doi.org/10.1136/bmjopen-2026-117263}
}

RIS

TY  - JOUR
TI  - Can sodium-glucose cotransporter 2 (SGLT2) inhibition preserve renal structure and function in de novo kidney transplant recipients? Protocol for a randomised, double-blind, placebo-controlled trial assessing the efficacy of dapagliflozin on kidney structure, function and safety in kidney transplant recipients in Norway—the DEAK study
AU  - Ingrid Charlotte Kongerud
AU  - Karsten Midtvedt
AU  - Marit D Solbu
AU  - Marius A Øvrehus
AU  - Øystein Eikrem
AU  - Ivar A Eide
AU  - Kristian Heldal
AU  - Kåre Birkeland
AU  - Anders Åsberg
AU  - Trond G Jenssen
PY  - 2026
JO  - BMJ Open
DO  - 10.1136/bmjopen-2026-117263
UR  - https://doi.org/10.1136/bmjopen-2026-117263
ER  -

APA

Kongerud, I. C., Midtvedt, K., Solbu, M. D., Øvrehus, M. A., Eikrem, Ø., Eide, I. A., Heldal, K., Birkeland, K., Åsberg, A., & Jenssen, T. G. (2026). Can sodium-glucose cotransporter 2 (SGLT2) inhibition preserve renal structure and function in de novo kidney transplant recipients? Protocol for a randomised, double-blind, placebo-controlled trial assessing the efficacy of dapagliflozin on kidney structure, function and safety in kidney transplant recipients in Norway—the DEAK study. BMJ Open. https://doi.org/10.1136/bmjopen-2026-117263

Source records

crossref · retrieved 2026-09-26T18:19:50.436Z